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Abstract Despite advancements in protocols, a subset of
melanocytic lesions continues to pose diagnostic chal-
lenges. This is particularly true in the pediatric population
where certain congenital nevi mimic melanoma. Recently,
comparative genomic hybridization (CGH) has been uti-
lized to support diagnoses of melanocytic lesions based on
DNA copy number changes. Because distinct differences in
copy number changes have been shown to occur in
malignant melanoma and benign nevi, CGH can be a
useful adjunct when diagnosis based on histology alone is
indeterminate. The authors discuss the benefits of using
CGH to aid in the diagnosis of melanocytic lesions that are
difficult to characterize as malignant or benign based on
clinical and histologic features alone. This paper presents a
brief clinical report and review of the literature. A 13-year-
old Caucasian male presented to an academic tertiary care
medical center after a shave biopsy unexpectedly revealed
malignant melanoma with positive deep margins. Follow-
ing complete excisional biopsy, the diagnosis of malignant
melanoma with depth of 0.92 mm was confirmed, both by
the home institution's pathologist and by consultant
dermatopathologists at two separate academic tertiary
medical centers. Sentinel lymph node biopsy revealed a
small focus of metastatic melanoma, this lead to a left-sided
modified radical neck dissection. All nodes removed were
negative for disease, and surgical and postsurgical care was
uncomplicated. Before proceeding with interferon therapy,
CGH was performed on the tissue from the primary lesion.
Other than a slight amplification of chromosome 16p, no
other aberrations were detected favoring a benign lesion.
Ultimately, the diagnosis was amended to compound
melanocytic nevus of the nose with benign nevus cell rest
in the sentinel node. While histopathologic evaluation is the
current gold standard for the diagnosis of melanoma, there
are many cases where it is inaccurate. TheuseofCGHinthe
evaluation of histologically equivocal lesions may allow
certain patients to avoid invasive procedures and associated
morbidities. The authors propose that, in these select diagnos-
tically challenging cases, tissue analyses by CGH may be
beneficial before proceeding to more invasive procedures such
as sentinel node biopsy and complete lymphadenectomy.
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Introduction
Current literature demonstrates poor concordance among
pathologists in diagnosing malignant melanoma [1, 2]. This
may be particularly true in the pediatric population where
certain melanocytic lesions such as Spitz nevi may be
impossible to differentiate from malignant melanoma based
on histology alone.
Sentinel lymph node biopsy (SLNB) has become a
standard component of melanoma management, and its
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understood [3, 4]. However, only a few small studies have
examined its efficacy and usefulness in the management of
pediatric melanoma [5–8]. When SLNB is positive for
spread of disease, the decision to perform complete lymph
node dissection (CLND) is often undertaken [8]. With
CLND comes an increased risk of morbidity. If benign
pathology can be established at the outset, morbidity from
wide resection SLNB and CLND can be prevented.
Recently, comparative genomic hybridization (CGH) has
been described as a potential adjunct in the diagnosis of
melanocytic lesions [9–13]. Based on known distinct DNA
copy number changes in melanoma and nevi, CGH can be
used to differentiate between malignant and benign lesions.
CGH can be a useful diagnostic tool for histologically
equivocal lesions and may prevent morbidity associated
with more invasive procedures.
Case report
A 13-year-old Caucasian male presented to an outside
physician for evaluation of an asymptomatic 4-mm uniformly
pigmented nevus on the left supratip region of his nose. The
lesion had been present since birth and had not changed in
size, symmetry, or color. The patient admitted to frequent sun
exposurebutdeniedanyhistoryofblisteringburns.Therewas
no family history of cutaneous malignancy. His medical
history and physical examination were otherwise unremark-
able. Given the very low suspicion of malignancy, a shave
biopsywas performed.Unexpectedly,pathologicexamination
revealed evidence of malignant melanoma involving the deep
marginsofthespecimen.Thepatientwasreferredtothesenior
author (A.S.M.) for further evaluation (Fig. 1).
A metastatic workup revealed no evidence of lymphade-
nopathyordistantmetastasis.Awidelocalexcisionwith1-cm
margins was performed under general anesthesia, and the
defect was reconstructed with a full-thickness skin graft
(Fig. 2). Histopathologic examination of the specimen
demonstrated a proliferation of single and nested melano-
cytes involving both the epidermis and dermis. These cells
were monomorphous with oval vesicular nuclei with both
pale and pigmented cytoplasm. There was maturation with
descent into the dermis. Dermal melanocytes tended to
aggregate around pilosebaceous units. A few mitotic figures
were limited to cells within the papillary dermis. In the
epidermis, there was some evidence of pagetoid spread, with
some single melanocytes reaching the cornified layer. Some
of these cells were dendritic with pigmented cytoplasm and
none were markedly atypical. Distinct uniform nucleoli were
seen in dermal and epidermal melanocytes. Evaluation by the
home institution's pathologist and by consultant dermatopa-
thologists at two separate academic tertiary medical centers
revealed the final diagnosis of malignant melanoma with a
depth of 0.92 mm.
The patient underwent sentinel lymph node biopsy after
confirmation of the diagnosis 2 months after the initial
shave biopsy. Initial lymphoscintigraphy of the face and
neck was performed. Intra-operatively, a single left jugulo-
digastric lymph node was identified by gamma probe
Fig. 1 The pigmented lesion is on the left supratip region of the nose
Fig. 2 A wide local excision with a 1-cm margin was performed, and
the defect was reconstructed with a full-thickness skin graft
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Histopathologic evaluation of the lymph node revealed a
single intracapsular focus of cells that were positive for
Melan-A. This focus was limited to a few single cells
clustered around a lymphatic one-cell stained positively for
HMB-45. Histologically, these cells resembled cells from
the primary lesion, and this was diagnosed as a small focus
of metastatic melanoma. Based on these findings, the
decision was made to perform a left-sided modified radical
neck dissection approximately 1 month later. During this
procedure, 53 lymph nodes from all five levels and the left
submandibular gland were removed. The spinal accessory
nerve, sternocleidomastoid muscle, jugular vein, and
parotid gland were spared, and the operation was uncom-
plicated. All 53 nodes and the submandibular gland were
negative for metastatic disease. The patient experienced no
post-operative complications other than a minor decrease in
neck range-of-motion which resolved with physical therapy.
Following the neck dissection, the patient's oncologist
recommended a 1-year course of interferon alpha-2b
therapy. Because of the associated toxicities of high-dose
interferon therapy, the patient's parents desired further
pathologic consultation before proceeding with treatment.
At that time, two expert dermatopathologists independently
reviewed the case and disagreed with the diagnosis of
melanoma. Instead, each favored a diagnosis of benign
nevus. Based on these conflicting opinions, the decision
was made to proceed with CGH to better support one single
diagnosis. Fixed tissue from both the shave and excision
biopsies was sent for evaluation. CGH demonstrated a
slight increase in tumor chromosome 16p profiles. However,
the tumor:reference signal intensity ratio was less than 1.2,
which was used as a cut-off for a true amplification.
Furthermore, chromosome 16p has been found to be
particularly susceptible to labeling artifacts which may lead
to false-positive increases in signal intensity [14]. Thus, the
increase in 16p was not considered to be abnormal. No other
chromosomal aberrations were detected. These findings were
consistent with a benign nevus rather than malignant
melanoma. Based on the corroboration of the latest histo-
pathologic evaluation and results of CGH, the diagnosis was
amended to compound melanocytic nevus of the nose.
Additionally, the sentinel lymph node lesion was reclassified
as a benign nevus cell rest.
Discussion
Melanoma comprises only 1-3% of all childhood cancers
[5–7]. Additionally, a subset of benign childhood melano-
cytic lesions such as Spitz nevi and certain congenital nevi
may mimic melanoma, potentially delaying intervention.
Even when such lesions are evaluated histologically, it is
often difficult to differentiate between benign nevi and
malignant melanoma.
The case presented illustrates this diagnostic challenge.
Clinically, the patient's lesions had characteristics consistent
with a benign etiology: it was present since birth, had not
changed in size or color, and was asymptomatic. Additionally,
the patient was an adolescent male and there was no family
history of melanoma. Histologically, there were features
favoring both benign (uniform cellular morphology, lack of
atypia, and maturation with decent) and malignant (pagetoid
spread and mitotic figures) etiologies, causing disagreement
between pathologists. In these cases, there is a need to
develop and implement the use of new diagnostic tools that
can serve as adjuncts to histopathologic evaluation.
CGH is a relatively new technique used to scan the entire
genome for chromosomal aberrations which are represented
by DNA copy number changes [10]. This technique utilizes
tissue from the tumor specimen as well as from a normal
human control specimen. The samples are labeled with
different fluorescent probes and then hybridized onto
metaphase spreads. DNA from the two samples competed
for chromosomal substrates. Based on measurements of
tumor-to-control fluorescence intensity, one can determine
whether DNA copy numbers in the tumor sample are
increased, decreased, or equivalent compared to those in
the control sample. Therefore, amplifications and deletions
of different chromosomal segments can be detected in the
tumor cells. Newer microarray-based methods allow for
maximum resolution and can detect even single copy
changes. One particular advantage of CGH is the ability to
micro-dissect tissue from samples that have already been
fixed [9]. Disadvantages include expense and the length of
time needed for the procedure.
As a research tool, CGH has been used to identify distinct
copy number changes in malignant melanoma and benign
melanocyticnevi[10–13, 15]. Bastian et al. [11] demonstrated
that while greater than 96% of malignant melanoma samples
demonstrated chromosomal aberrations, most benign nevi did
not. Aberrations most commonly found in melanoma samples
were gains of chromosomes 6p, 1q, 7p, 7q, 8q, 17q, and 20q;
and losses of 9p, 9q, 10q, 10p, 6q, and 11q. Interestingly,
while most benign nevi show no aberrations, Spitz nevi tend
to demonstrate isolated gains of 11p, a change that is not
typically observed in malignant melanoma [10–12]. Benign
proliferations arising within congenital melanocytic nevi
(CMN) have also been found to have chromosomal aberra-
tions [13]. However, these differ from aberrations found in
malignant melanomas arising from CMN, which are similar
to those found in melanomas that arise de novo. While
sample sizes used in these studies are relatively small, the
results are promising and highlight the potential role of CGH
as a tool to aid in the differentiation of benign and malignant
melanocytic lesions.
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limited to a small number of cases. Its utility in confirming the
histologic diagnosis of a benign nodule developing within a
CMN in an infant was documented in a recent case report by
Murphy et al. [9]. In the case of our 13-year-old patient, the
use of CGH has important implications. Currently, little data
exists regarding the usefulness of SLNB in malignant
melanomas less than 1.0 mm deep, particularly in children.
Such lesions may pose clinical decision-making challenges,
especially when evidence of malignancy is not entirely certain
based on histology. Furthermore, while SLNB is a useful
tool for detecting nodal metastases, it does not always
differentiate between malignant and benign lesions.
Benign nevus-cell aggregates in lymph nodes are known
to occur with benign primary lesions and in up to 22%
of malignant melanomas [16, 17]. Any of these factors
may have contributed to our patient's unnecessary surgical
interventions. Fortunately, the patient did not experience
any of the significant morbidities associated with CLND.
However, had CGH been utilized earlier in the diagnostic
process, the patient may have been able to avoid SLNB
and CLND altogether. Thus, in cases where there is such
uncertainty regarding diagnosis and treatment, the authors
propose the use of CGH to support tissue diagnosis and to
guide treatment plans.
Conclusion
Theuncertainnatureofa subsetofmelanocytic nevi,basedon
histology alone, warrants the development and implementa-
tion of better adjunctive diagnostic tools. As a research tool,
CGH has identified several distinct differences in DNA copy
number changes in malignant melanoma and benign nevi.
Based on these known differences, CGH can serve as a
potentially useful diagnostic tool in the clinical setting when
lesions demonstrate equivocal histology. By helping to
support histologic diagnoses, CGH may allow certain patients
to avoid unnecessary invasive procedures such as CLND that
are associated with significant morbidity. However, before the
use of this method can become widespread, larger studies
need to be conducted to better classify distinctions between
malignant and benign melanocytic lesions.
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